Fig. 1: Trial profile.

Patients with tumor sample available (ITT population, n = 339) were allocated to randomization to F1CDX (n = 171) or CTL (n = 168). Molecular profile analysis failed in 13 patients for both panels (F1CDX: n = 5, CTL: n = 8), and 17 patients had a molecular profile achieved from a single panel (F1CDX: n = 10, CTL: n = 7). Molecular profiles achieved with both panels were available for 309 patients (per protocol population). Two gene panels were used: F1CDX (324 genes) and a home-based limited panel (CTL) (87 genes). At patient progression, the MTB reviewed genomic alterations matching with at least one MBRT based on the first panel as defined per randomization. In the case of failure (no MBRT identified with the first panel), the second panel was disclosed. Among the 339 patients, an MBRT was identified in 192 (56.6%) patients and an MBRT was initiated in 51 (15%) patients. Of note, 17 deaths occurred during screening, and tumor samples were not collected from these patients. A total of 58 patients died after randomization and before MTB review. However, their molecular profiles had been considered for MTB review at the date of data cutoff, and MBRTs were recorded (no MBRT: n = 25 (F1CDX: 12, CTL: 13); MBRTs: n = 33 (F1CDX: 19, CTL: 14)). A total of 233 deaths occurred during the study period.